Regeneron Pharmaceuticals Inc. (REGN) has reported progress in its efforts to develop what it describes as a "multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as a treatment for those already infected." In addition, Regeneron said antibodies from humans who have recovered from Covid-19 "have been isolated to maximize the pool of potentially potent antibodies."
More from Stocks
I use the shark metaphor to illustrate the advantage that small investors have over the Wall Street whales.
Let's use the chart of Fastly to examine the roles of price, trend, momentum, and volume.
It is tough for the bears to gain traction with their macro arguments, when dip buyers and aggressive pockets of trading action remain -- so continue to look to price action for guidance.
Nothing seems to matter anymore except which stock to buy, a staggering conclusion with 11% unemployment and a raging epidemic.